Company intelligence / Profile preview
Anika Therapeutics
- Ownership
- Public · ANIK
- Employees
- ~350
- Development stage
- Commercial
Overview
Anika has multiple commercialized products for osteoarthritis pain management and regenerative orthopedic solutions. Its lead pipeline product "Hyalofast" completed pivotal Phase III enrollment in the US as of late 2023. The company’s Integrity™ Implant System for tendon repair received FDA clearance and launched commercially in the US in early/mid–2024. Tactoset®, an HA-enhanced bone substitute, has expanded FDA clearances including use with autologous bone marrow aspirate.
- Therapeutic areas
- OtherRheumatology
- Modalities
- BiologicDeviceHydrogel-based drug delivery therapyRecombinant protein (hyaluronic acid-based)
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $258.7M
- Total revenue
- $112.8M
- Enterprise value
- $243.6M
Beyond the preview
Go deeper on Anika Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anika Therapeutics.